CD8A and plasma cell myeloma: Such protective anti-myeloma immunity was clone-specific and mainly conferred by IFNγ-secreting CD8+ T cells, also being further enhanced by a CD137 agonist and IL-17A inhibition, thus representing a potential therapeutic approach to improve the autologous graft-versus-myeloma effect [87].